Shares of clinical-stage biopharma Cara Therapeutics (
The drug achieved a 68% reduction in itching compared to placebo after eight weeks of treatment and was well tolerated.
The latest development marks yet another positive development for investors in the last six months. While CR845 will soon enter the pivotal part B of the chronic kidney disease-associated pruritus trial, the study is not the most advanced in the company's pipeline.
As investors are well aware, Cara Therapeutics' stock has more than doubled since late 2016 on...